Skip to Main Content

Author Details

Janet L Anderl
Onyx Pharmaceuticals, Inc.
2009
17
13
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36969170Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses.Front Immunol2023
37169961Signal peptide mimicry primes Sec61 for client-selective inhibition.Nat Chem Biol2023
34234005Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the Immunoproteasome.Drug Metab Dispos2021
30380863Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).J Med Chem2018
29182146Immunoproteasome functions explained by divergence in cleavage specificity and regulation.Elife2017
28435528Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.ACS Med Chem Lett2017
27207788CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.Blood2016
25308268Analysis of autophagosome formation using lentiviral biosensors for live fluorescent cellular imaging.Methods Mol Biol2015
24418325Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.J Hematol Oncol2014
25612802Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.J Exp Clin Cancer Res2014
24737138Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).Mol Pharmacol2014
24552657Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.Biochem Pharmacol2014
23305345Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.Exp Hematol Oncol2013
24056819Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Haematologica2013
23592311Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.Hum Mutat2013
21364033Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.Clin Cancer Res2011
19417729A neuronal and astrocyte co-culture assay for high content analysis of neurotoxicity.J Vis Exp2009
  • 1 - 17 of 17

Recommended Authors

Ian D Ferguson
Yale University School of Medicine
Career Start Year 2015
Number of shared co-authors 2
Zhiyuan Mao
College of Life Science and Engineering, Southwest Jiaotong University
Career Start Year 2015
Number of shared co-authors 0
Allison W Roberts
University of California berkeley
Career Start Year 2011
Number of shared co-authors 0
Nehme El-Hachem
Centre Hospitalier Universitaire Sainte-Justine Research Centre
Career Start Year 2011
Number of shared co-authors 0
Jisun Kim
University of Toronto
Career Start Year 2009
Number of shared co-authors 0
Ahmed Aman
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2007
Number of shared co-authors 1
Thomas B Sundberg
Cutaneous Biology Research Center
Career Start Year 2006
Number of shared co-authors 0
Dhiraj Kumar
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 1
Luke L Lairson
The Scripps Research Institute
Career Start Year 2003
Number of shared co-authors 0
Steven W Millward
University of Texas MD Anderson Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Huib Ovaa
Leiden University Medical Center
Career Start Year 2002
Number of shared co-authors 1
Noel Southall
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 1
Craig J Thomas
Center for Cancer Research, National Cancer Institute
Career Start Year 2001
Number of shared co-authors 0
Cristina C Clement
Englander Institute for Precision Medicine
Career Start Year 2001
Number of shared co-authors 0
Jason E Gestwicki
Institute for Neurodegenerative Diseases, University of California San Francisco
Career Start Year 2000
Number of shared co-authors 9
Jaime H Cheah
Johns Hopkins University School of Medicine
Career Start Year 2000
Number of shared co-authors 0
Sunil K Joshi
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 0
Brent R Stockwell
Columbia University
Career Start Year 1998
Number of shared co-authors 0
Clifton L Dalgard
Uniformed Services University of the Health Sciences
Career Start Year 1997
Number of shared co-authors 0
Ranjini K Sundaram
Yale University
Career Start Year 1996
Number of shared co-authors 0
Deborah Lawson
Oncology R&D
Career Start Year 1996
Number of shared co-authors 0
Michael Ohlmeyer
Atux Iskay LLC
Career Start Year 1993
Number of shared co-authors 0
Huy Nguyen
The University of Danang-University of Science and Technology
Career Start Year 1993
Number of shared co-authors 0
Zhiqiang An
Zhengzhou University
Career Start Year 1992
Number of shared co-authors 0
Marc Ferrer
National Institutes of Health, National Center for Advancing Translational Sciences
Career Start Year 1992
Number of shared co-authors 0
Alessandro Datti
University of Perugia
Career Start Year 1991
Number of shared co-authors 1
Yue-Ming Li
Memorial Sloan Kettering Cancer Center
Career Start Year 1990
Number of shared co-authors 0
Christopher P Austin
St. George's University Medical School
Career Start Year 1990
Number of shared co-authors 0
Ronald C Hendrickson
Memorial Sloan Kettering Cancer Center
Career Start Year 1990
Number of shared co-authors 0
Timothy A Lewis
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1990
Number of shared co-authors 0

Collaborators

Shirin Arastu-Kapur
Stanford University School of Medicine
Co-authored papers 3
Andrej Sali (CM4AI)
University of California San Francisco
Co-authored papers 1
Florencia La Greca
Department of Pharmaceutical Chemistry , University of California san francisco
Co-authored papers 1
Francesco Caiazza
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 1
Michael Slifker
Fox Chase Cancer Center
Co-authored papers 1
Phillip P Sharp
University of California san francisco
Co-authored papers 1
Nicole A Wenzell
Quantitative Biosciences Institute (QBI), University of California San Francisco
Co-authored papers 1
Anthony J O'Donoghue
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Co-authored papers 1
Jack Taunton
University of California san francisco
Co-authored papers 1
Christoph Driessen
Cantonal Hospital St. Gallen
Co-authored papers 1
Matthew Ravalin
Stanford University
Co-authored papers 1
Michael B Winter
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 1
Markus-Frederik Bohn
Department of Pharmaceutical Chemistry, University of California San Francisco
Co-authored papers 1
Charles S Craik
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 1
Matthew P Jacobson
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 1
Aaron D Schimmer
Princess Margaret Cancer Centre
Co-authored papers 1
Chakrapani Kalyanaraman
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 1
Juha T Huiskonen
Institute of Biotechnology, University of Helsinki
Co-authored papers 1
Peter Cimermancic
Verily Life Sciences LLC
Co-authored papers 1
Tonia J Buchholz
Onyx Pharmaceuticals, Inc.
Co-authored papers 1
Release 1.2